Details for Patent: RE41489
✉ Email this page to a colleague
Summary for Patent: RE41489
| Title: | Method of providing sustained analgesia with buprenorphine |
| Abstract: | A method of effectively treating pain in humans is achieved by administering buprenorphinein accordance with first order kinetics over an initial three-day dosing interval, such that a maximum plasma concentration from about 20 pg/ml to about 1052 pg/ml is attained, and thereafter maintaining the administration of buprenorphine for at least an additional two-day dosing interval in accordance with substantially zero order kinetics, such that the patients experience analgesia throughout the at least two-day additional dosing interval. |
| Inventor(s): | Robert F. Reder, Robert F. Kaiko, Paul D. Goldenheim |
| Assignee: | Purdue Pharma LP |
| Application Number: | US11/799,611 |
|
Patent Claim Types: see list of patent claims | Use; Delivery; |
Drugs Protected by US Patent RE41489
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent RE41489
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Austria | 336212 | ⤷ Start Trial | |||
| Austria | 538765 | ⤷ Start Trial | |||
| Austria | 556682 | ⤷ Start Trial | |||
| Australia | 2004218685 | ⤷ Start Trial | |||
| Australia | 2008261134 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
